Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2016
At a glance
- Drugs AGN 232411 (Primary)
- Indications Dry eyes
- Focus Adverse reactions
- Sponsors Allergan
- 13 Jul 2016 Status changed from recruiting to completed.
- 06 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 23 Apr 2015 New trial record